Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23000897 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Lapatinib;   Drug: Trastuzumab;   Drug: Endocrine Therapy;   Drug: Paclitaxel

Indicates status has not been verified in more than two years